Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Locke, Frederick L.; Rossi, John M.; Neelapu, Sattva S.; Jacobson, Caron A.; Miklos, David B.; Ghobadi, Armin; Oluwole, Olalekan O.; Reagan, Patrick M.; Lekakis, Lazaros J.; Lin, Yi; Sherman, Marika; Better, Marc; Go, William Y.; Wiezorek, Jeffrey S.; Xue, Allen; Bot, Adrian

doi:10.1182/bloodadvances.2020002394

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for …